A myeloperoxidase promoter polymorphism is independently
associated with mortality in patients with impaired left
ventricular function.

J 2009

A myeloperoxidase promoter polymorphism is independently associated with mortality in patients with impaired left ventricular function.

RUDOLPH, V; TK RUDOLPH; Lukáš KUBALA; N CLAUBERG; R MAAS et al.

Základní údaje

Originální název

A myeloperoxidase promoter polymorphism is independently associated with mortality in patients with impaired left ventricular function.

Autoři

RUDOLPH, V; TK RUDOLPH; Lukáš KUBALA; N CLAUBERG; R MAAS; Michaela PEKAROVÁ; A KLINKE; D LAU; Katalin SZÖCS; T MEINERTZ; RH BÖGER a S BALDUS

Vydání

FREE RADICAL BIOLOGY AND MEDICINE, New York, NY, USA, ELSEVIER SCIENCE INC, 2009, 0891-5849

Další údaje

Typ výsledku

Článek v odborném periodiku

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 6.081

Označené pro přenos do RIV

Organizační jednotka

Přírodovědecká fakulta

DOI

https://doi.org/10.1016/j.freeradbiomed.2009.09.001

UT WoS

000271934300008

Klíčová slova česky

Myeloperoxidase; Genetics; Heart failure; Survival; Free radicals

Klíčová slova anglicky

Myeloperoxidase; Genetics; Heart failure; Survival; Free radicals

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 28. 5. 2012 21:03, Mgr. Michaela Pekarová, Ph.D.

Anotace

V originále

Circulating levels of myeloperoxidase (MPO), a heme enzyme released upon activation of polymorphonuclear neutrophils, predict adverse outcome in patients with impaired left ventricular (LV) function.Interestingly, we observed no association of the MPO polymorphism with total MPO protein concentration or MPO activity in plasma. The 463 GA MPO polymorphism is linked to adverse clinical outcome of patients with impaired LV function. Further studies are needed to elucidate the value of this polymorphism for risk stratification.

Citovat

RUDOLPH, V; TK RUDOLPH; Lukáš KUBALA; N CLAUBERG; R MAAS; Michaela PEKAROVÁ; A KLINKE; D LAU; Katalin SZÖCS; T MEINERTZ; RH BÖGER a S BALDUS. A myeloperoxidase promoter polymorphism is independently associated with mortality in patients with impaired left ventricular function. FREE RADICAL BIOLOGY AND MEDICINE. New York, NY, USA: ELSEVIER SCIENCE INC, 2009, roč. 47, č. 11, s. 1584-90, 7 s. ISSN 0891-5849. Dostupné z: https://doi.org/10.1016/j.freeradbiomed.2009.09.001.

@article{983201,
   author = {Rudolph, V and Rudolph, TK and Kubala, Lukáš and Clauberg, N and Maas, R and Pekarová, Michaela and Klinke, A and Lau, D and Szöcs, Katalin and Meinertz, T and Böger, RH and Baldus, S},
   article_location = {New York, NY, USA},
   article_number = {11},
   doi = {https://doi.org/10.1016/j.freeradbiomed.2009.09.001},
   keywords = {Myeloperoxidase; Genetics; Heart failure; Survival; Free radicals},
   issn = {0891-5849},
   journal = {FREE RADICAL BIOLOGY AND MEDICINE},
   title = {A myeloperoxidase promoter polymorphism is independently associated with mortality in patients with impaired left ventricular function.},
   url = {http://www.ncbi.nlm.nih.gov/pubmed/19735726},
   volume = {47},
   year = {2009}
}

TY  - JOUR
ID  - 983201
AU  - Rudolph, V - Rudolph, TK - Kubala, Lukáš - Clauberg, N - Maas, R - Pekarová, Michaela - Klinke, A - Lau, D - Szöcs, Katalin - Meinertz, T - Böger, RH - Baldus, S
PY  - 2009
TI  - A myeloperoxidase promoter polymorphism is independently associated with mortality in patients with impaired left ventricular function.
JF  - FREE RADICAL BIOLOGY AND MEDICINE
VL  - 47
IS  - 11
SP  - 1584-90
EP  - 1584-90
PB  - ELSEVIER SCIENCE INC
SN  - 08915849
KW  - Myeloperoxidase
KW  - Genetics
KW  - Heart failure
KW  - Survival
KW  - Free radicals
UR  - http://www.ncbi.nlm.nih.gov/pubmed/19735726
N2  - Circulating levels of myeloperoxidase (MPO), a heme enzyme released upon activation of polymorphonuclear neutrophils, predict adverse outcome in patients with impaired left ventricular (LV) function.Interestingly, we observed no association of the MPO polymorphism with total MPO protein concentration or MPO activity in plasma. The 463 GA MPO polymorphism is linked to adverse clinical outcome of patients with impaired LV function. Further studies are needed to elucidate the value of this polymorphism for risk stratification.
ER  -

RUDOLPH, V; TK RUDOLPH; Lukáš KUBALA; N CLAUBERG; R MAAS; Michaela PEKAROVÁ; A KLINKE; D LAU; Katalin SZÖCS; T MEINERTZ; RH BÖGER a S BALDUS. A myeloperoxidase promoter polymorphism is independently associated with mortality in patients with impaired left ventricular function. \textit{FREE RADICAL BIOLOGY AND MEDICINE}. New York, NY, USA: ELSEVIER SCIENCE INC, 2009, roč.~47, č.~11, s.~1584-90, 7 s. ISSN~0891-5849. Dostupné z: https://doi.org/10.1016/j.freeradbiomed.2009.09.001.

Přehled o publikaci